Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

FitteR-CATABOLIC

Financiado

Cerrado

Survival of the Fittest On how to enhance recovery from critical illness throug...

Survival of the Fittest On how to enhance recovery from critical illness through learning from evolutionary conserved catabolic pathways Since a few decades, human patients who suffer from severe illnesses or multiple trauma, conditions that were previously lethal, are being treated in intensive care units (ICUs). Modern intensive care medicine bridges patients fro... ver más

31/03/2024

KU Leuven

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

KATHOLIEKE UNIVERSITEIT LEUVEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2024-03-31

ERC-2017-ADG: ERC Advanced Grant

I+D

Cerrada hace 7 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

KU Leuven

2.50M€ | Lider

INTEGRA LABORATORIOS

350.00K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

AdrenalWeakness Concomitant Reversal of Adrenal Insufficiency and Muscle Wea... 2M€ Cerrado

Nutri-CARE Nutri CARE Nutrient restriction during Critical illness fr... 3M€ Cerrado

COPD-HIT Innovative treatment for extrapulmonary benefits in COPD: ef... 1M€ Cerrado

TIN2012-38450-C03-03 RAZONAMIENTO BASADO EN CASOS PARA OPTIMIZACION DE LA REHABIL... 103K€ Cerrado

TIN2012-38450-C03-02 ANALISIS MULTIPARAMETRICO DE IMAGEN, CLINICA Y TERAPIA PARA... 15K€ Cerrado

TIN2012-38450-C03-01 ANALISIS MULTIPARAMETRICO DE IMAGEN, CLINICA Y TERAPIA PARA... 129K€ Cerrado

Duración del proyecto: 67 meses Fecha Inicio: 2018-08-22
Fecha Fin: 2024-03-31

Líder del proyecto

KATHOLIEKE UNIVERSITEIT LEUVEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Since a few decades, human patients who suffer from severe illnesses or multiple trauma, conditions that were previously lethal, are being treated in intensive care units (ICUs). Modern intensive care medicine bridges patients from life-threatening conditions to recovery with use of mechanical devices, vasoactive drugs and powerful anti-microbial agents. By postponing death, a new unnatural condition, intensive-care-dependent prolonged (>1 week) critical illness, has been created. About 25% of ICU patients today require prolonged intensive care, sometimes for weeks or months, and these patients are at high risk of death while consuming 75% of resources. Although the primary insult was adequately dealt with, many long-stay patients typically suffer from hypercatabolism, ICU-acquired brain dysfunction and polyneuropathy/myopathy leading to severe muscle weakness, further increasing the risk of late death. As hypercatabolism was considered the culprit, several anabolic interventions were tested, but these showed harm instead of benefit. We previously showed that fasting early during illness is superior to forceful feeding, pointing to certain benefits of catabolic responses. In healthy humans, fasting activates catabolism to provide substrates essential to protect and maintain brain and muscle function. This proposal aims to investigate whether evolutionary conserved catabolic fasting pathways, specifically lipolysis and ketogenesis, can be exploited in the search for prevention of brain dysfunction and muscle weakness in long-stay ICU patients, with the goal to identify a new metabolic intervention to enhance their recovery. The project builds further on our experience with bi-directional translational research - using human material whenever possible and a validated mouse model of sepsis-induced critical illness for objectives that cannot be addressed in patients - and aims to close the loop, from a novel concept to a large randomized controlled trial in patients.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores